NYSE · PFE
Pfizer Inc.
$29.95+$0.50 (+1.7%)
Pfizer Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.61% below the high.
Loading market information…
NASDAQ · PCVX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Vaxcyte, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.01% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Vaxcyte, Inc.’s next earnings report is currently expected on Nov 3, 2026, with estimated earnings per share of -$2.11. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Vaxcyte, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q4 2024 | Feb 25, 2025 | -$1.02+12.07% vs estimate | $0.00 |
|---|
| Q3 2024 | Nov 5, 2024 | -$0.83+24.55% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
11 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $122.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$29.95+$0.50 (+1.7%)
Pfizer Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.61% below the high.
$48.68-$0.06 (-0.12%)
GSK plc’s quoted price sits in the lower half of its reported 52-week range, 21.1% below the high.
$222.76+$8.60 (+4.01%)
Moderna, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.46% below the high.
$8.74-$0.07 (-0.79%)
ImmunityBio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 29.69% below the high.
$11.75-$0.18 (-1.51%)
Vir Biotechnology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.61% below the high.
$10.47+$0.15 (+1.45%)
Novavax, Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.81% below the high.
$5.71-$0.03 (-0.52%)
Valneva SE’s quoted price sits in the lower half of its reported 52-week range, 53.12% below the high.
$12.15+$0.08 (+0.66%)
Arcturus Therapeutics Holdings Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.35% below the high.
